Evaxion Biotech A/S (EVAX)

Operator: Hello, and welcome to the Evaxion Business Update and Third Quarter 2025 Financial Results. [Operator Instructions] Please be advised that today's conference is being recorded.

Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential.

On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.

Operator: Hello, and welcome to Evaxion's Second Quarter 2025 Conference Call. [Operator Instructions] I would now like to turn the conference over to Birgitte Rono, Interim CEO and CSO.

The funds will be used to support research into identifying and combining antigens to create a new vaccine design that does not utilize live viruses.

Operator: Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast.

Operator: Good day and thank you for standing by. Welcome to the Evaxion Biotech Business Update Conference call. [Operator Instructions] Please be advised, that today's conference is being recorded.

Christian Kanstrup: Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results. I'm Christian Kanstrup. I'm the CEO of Evaxion.